Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses

Liubov I Kozlovskaya,Viktor P Volok,Anna A Shtro,Yulia V Nikolaeva,Alexey A Chistov,Elena S Matyugina,Evgeny S Belyaev,Artjom V Jegorov,Robert Snoeck,Vladimir A Korshun,Graciela Andrei,Dmitry I Osolodkin,Aydar A Ishmukhametov,Andrey V Aralov,Liubov I. Kozlovskaya,Viktor P. Volok,Anna A. Shtro,Yulia V. Nikolaeva,Alexey A. Chistov,Elena S. Matyugina,Evgeny S. Belyaev,Artjom V. Jegorov,Vladimir A. Korshun,Dmitry I. Osolodkin,Aydar A. Ishmukhametov,Andrey V. Aralov

DOI: https://doi.org/10.1016/j.ejmech.2021.113467

IF: 7.088

2021-08-01

European Journal of Medicinal Chemistry

Abstract:Emerging and re-emerging viruses periodically cause outbreaks and epidemics all over the world, eventually leading to global events such as the current pandemic of the novel SARS-CoV-2 coronavirus infection COVID-19. Therefore, an urgent need for novel antivirals, is crystal clear. Here we present the synthesis and evaluation of an antiviral activity of phenoxazine-based nucleoside analogs divided into three groups: (1) 8-alkoxy-substituted, (2) acyclic, and (3) carbocyclic. The antiviral activity was assessed against a structurally and phylogenetically diverse panel of RNA and DNA viruses from 25 species. Four compounds (11a-c, 12c) inhibited 4 DNA/RNA viruses with EC50 ≤ 20 μM. Toxicity of the compounds for the cell lines used for virus cultivation was negligible in most cases. In addition, previously reported and newly synthesized phenoxazine derivatives were evaluated against SARS-CoV-2, and some of them showed promising inhibition of reproduction with EC50 values in low micromolar range, although, accompanied by commensurate cytotoxicity.

chemistry, medicinal